placeholder
Importance
55
Trust
80
Urgency
30
REGULATORY · PRIMARY SOURCE
D&H Medical Services - 728238 - 06/08/2026
The FDA told D&H Medical Services to stop making false claims about its compounded weight-loss drugs semaglutide and tirzepatide. The company claimed its copies were the "same ingredient" as the brand-name drugs Ozempic, Rybelsus, and Mounjaro, but compounded drugs are not FDA-approved and cannot make those claims.
Analysis
FDA keeps pushing compounders off brand-name GLP-1 turf. That steers patients back to Novo's Ozempic and Lilly's Mounjaro at full price.
- FDA issued warning letter MARCS-CMS 728238 to D&H Medical Services on June 8, 2026
- D&H claimed compounded semaglutide/tirzepatide were 'Same ingredient as Ozempic®', 'Same ingredient as Mounjaro®'
- FDA reviewed D&H's website in March 2026; company must respond within 15 business days
FDA Drug Approvals & Databases4d
Read